linjc16/ctgov huggingface dataset:
Position of the Endotracheal Tube Cuff in Relation to Cricoid in Children.

Study Overview
=================
Brief Summary
-----------------
To verify the exact location of cuff of the endotracheal tube in children.

Detailed Description
-----------------
The exact location of the cuff of the endotracheal tube in children has not been studied. This study is the first attempt to verify the position of the cuff in the airway with relation to cricoid.

Official Title
-----------------
Consultant Anesthesiology

Conditions
-----------------
D009863

Intervention / Treatment
-----------------
* Radiation: XRay


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children aged 1 month to 8 years Exclusion Criteria: Any airway pathology

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 8 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Radiation: XRay|Xray to confirm the location of the endotracheal tube|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cuff position | Location of the cuff of the ETT | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
airway, children, endotracheal tube, cuff
Measurements of Resting Energy Expenditure in Patients With or at Risk of Developing Graft Versus Host Disease

Study Overview
=================
Brief Summary
-----------------
This study aims to show that the MedGem indirect calorimetry measurement device will be feasible to use in children with GVHD. Also, it aims to show that children with chronic GVHD will have elevated REE that is not adequately predicted by standard equations.

Detailed Description
-----------------
Chronic Graft versus Host Disease (GVHD) is an important cause of morbidity and mortality in patients undergoing allogeneic bone marrow and hematopoietic progenitor cell transplantation. In adults, it has been shown that patients with acute or chronic GVHD have an increase in their resting energy expenditure (REE), likely as a result of chronic systemic inflammation. These studies have not yet been performed in children. This study's objective is to determine the REE of pediatric patients with acute and chronic GVHD after hematopoietic stem cell transplantation (HSCT).

Official Title
-----------------
Measurements of Resting Energy Expenditure in Patients With or at Risk of Developing Graft Versus Host Disease

Conditions
-----------------
Graft-Versus-Host Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects must be 7-30 years of age Signed informed consent One of the following three criteria must be met: Presence of grade II or greater acute GVHD as defined by Keystone criteria Presence of clinically extensive chronic GVHD as defined by the revised Seattle criteria Any subject identified prior to allogeneic transplant, or following allogeneic transplant, who is at risk for acute or chronic GVHD Exclusion Criteria: Inability to meet the requirements of the study procedures Any subject who is receiving supplemental oxygen Withdrawal of consent

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| High risk<br>Patients who are at high risk of developing acute or chronic GVHD | |
| GVHD<br>Patients who currently have either grade II or greater acute GVHD, or clinically extensive chronic GVHD | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Feasibility - can the procedure be adequately performed in a child? |  | Spring of 2012 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measure of resting energy expenditure - kcal/day and oxygen consumption (VO2 mL/min) |  | Spring of 2012 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Graft-Versus-Host Disease, Transplantation, Allogeneic, Transplantation, Hematopoietic Stem Cell, Calorimetry, Respiration
3D Printed Assistive Devices for Individuals With Physical Disabilities

Study Overview
=================
Brief Summary
-----------------
Our research aims to examine 3D printed device satisfaction when using mobile devices for individuals with physical disabilities in long-term care facilities, and the impact of the 3D printed device integration on overall occupational performance and satisfaction.

Detailed Description
-----------------
This feasibility study will be conducted at Good Shepherd Rehabilitation Network (GSRN) in the collection of data examining 3D printing outcomes. The 3D printed devices are within the current normal and customary care of GSRN services, with the focus on the created 3D printed adaptations for mobile device usage (i.e. smartphone adaptations). The feasibility data will assist in understanding the satisfaction and performance of 3D printed devices for persons with a physical disability.

Official Title
-----------------
Satisfaction of 3D Printed Assistive Devices for Individuals With Physical Disabilities Living in a Long-Term Care Setting

Conditions
-----------------
Disability Physical

Intervention / Treatment
-----------------
* Other: Custom 3D printed device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Being over the age of 18 Self-identified accessibility needs of the mobile device to address secondary to a physical accessibility limitation(s) Accessibility requests of a device that has not already been addressed by 3D printing Ownership or borrowing of a mobile device for personal use Operational definition of mobile devices: Mobile devices are a maximum length and width of 9.4 by 6.8 and must weigh less than 1.03 lb (e.g. dimensions of a standard iPad mini) and should be a one-handed use device with touch-screen capabilities Exclusion Criteria: Individuals with severe cognitive impairment (BIMS score of 7 or less) Individuals who were unwilling to use a 3D printed device

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Custom 3D printed device|A 3D printed adaptation for a mobile device.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Canadian Occupational Performance Measure (COPM) | As a self-reported measure of occupational performance and occupational satisfaction, the scale ranges from 1-10, with 10 indicating a more favorable outcome in self-rated occupational performance and satisfaction. | 3-4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0) | Participants will self-report satisfaction with the created and printed device and service on a Likert scale from 1-5, with 5 indicating maximum satisfaction. | 3-4 weeks |
Project Resurgence Communication Trial

Study Overview
=================
Brief Summary
-----------------
Randomized, double-blind, of standard of care vs additional communication and factorial design of intervention letter vs. control letter and EHR vs mail delivery mechanism in patients who canceled visits and did not reschedule over a 90 day period starting March 9, 2020.

Official Title
-----------------
Comparison of the Effectiveness of Communication Strategies on the Return to In-Person Visits to a Medical Center After the Emergence of COVID-19: A Randomized Trial

Conditions
-----------------
Communication Research

Intervention / Treatment
-----------------
* Other: Communication type


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a cancellation or failure to show for a procedure or visit from March 9, 2020 through June 7, 2020 (90 days) and who have not rescheduled as of the date of randomization Exclusion Criteria: Death
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Factorial Assignment
Interventional Model Description: Randomized, double-blind, factorial design
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: No intervention<br> | |
| Active Comparator: MPM control letter<br> | Other: Communication type<br>* Control letter vs. intervention letter<br>|
| Experimental: MPM intervention letter<br> | Other: Communication type<br>* Control letter vs. intervention letter<br>|
| Active Comparator: Mailed control letter<br> | Other: Communication type<br>* Control letter vs. intervention letter<br>|
| Experimental: Mailed intervention letter<br> | Other: Communication type<br>* Control letter vs. intervention letter<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent of Participants With Visit or Procedure With Provider |  | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent of Participants With Scheduled Visit or Procedure With Provider |  | 1 month | 
| Percent of Participants With Completed Telemedicine Visit With Provider |  | 1 month |
Sublingual Methadone for the Management of Cancer Breakthrough Pain

Study Overview
=================
Brief Summary
-----------------
A dose titration protocol for sublingual methadone hydrochloride for the management of cancer-related breakthrough pain to find the optimal dose.

Detailed Description
-----------------
This is a dose titration protocol for sublingual methadone hydrochloride for the management of cancer-related breakthrough pain to find the optimal dose.

Official Title
-----------------
Evaluation of a Dose Titration Protocol for Sublingual Methadone Hydrochloride for the Management of Cancer-related Breakthrough Pain

Conditions
-----------------
Cancer, Pain

Intervention / Treatment
-----------------
* Drug: Methadone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: > 18 years of age Experiences episodes of breakthrough pain which respond to opioid therapy Controlled baseline pain Cognitive status sufficient for accurate completion of assessment form Willing to provide written informed consent Ability to hold a volume of 1 cc of water under the tongue for 5 minutes Exclusion Criteria: Currently or has received methadone during the previous week Recent history of substance abuse Severe respiratory impairment or other contraindications to opioids Recently received therapies that had the potential to alter pain intensity or response to analgesics Symptomatic anemia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Methadone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine optimal dose titration |  |  | 
| Determine assessment protocol |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cancer pain, breakthrough pain, methadone, dose titration, sublingual route of administration, Cancer related pain, currently taking narcotics
A Study to Define the Distribution of Type of Hypertension in Asia by Blood Pressure Monitoring at Home (Asia BP@Home)

Study Overview
=================
Brief Summary
-----------------
Blood pressure variability (BPV) is being increasingly recognized as an important influence on hypertension outcomes as well as a risk factor for other cardiovascular (CV) events. However, in Asia there is a current lack of awareness of BPV and its significance on patient outcomes. Furthermore, there is ongoing debate on the role of home blood pressure (HBP) monitoring in managing hypertension patients and uncertainty on how best to integrate it into clinical practice. Therefore, we conduct Asia BP@Home study to assess HBP control status in each Asian country and develop an Asian consensus and Asia-specific treatment for hypertension.

Detailed Description
-----------------
Blood pressure variability (BPV) is being increasingly recognized as an important influence on hypertension outcomes as well as a risk factor for other cardiovascular (CV) events. However, in Asia there is a current lack of awareness of BPV and its significance on patient outcomes. Furthermore, there is ongoing debate on the role of home blood pressure (HBP) monitoring in managing hypertension patients and uncertainty on how best to integrate it into clinical practice. The main purpose of this study is to: Assess HBP control status in each Asian country Develop an Asian consensus and Asia-specific treatment for hypertension Improve the management of hypertension in Asia by encouraging patients to monitor HBP

Official Title
-----------------
A Study to Define the Distribution of Type of Hypertension in Asia by Blood Pressure Monitoring at Home (Asia BP@Home)

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Other: home blood pressure measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >= 20 years Subjects with stable medication (> 3 months) diagnosed as hypertension Asian Subjects have been thoroughly informed about this registry and signed an Informed Consent Form. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: home blood pressure measurement|We ask participants to measure their home blood pressure 7 days or more.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distribution rate based on the home BP of the patients. | Distribution rate based on the home BP of the patients who are defined as: Masked morning hypertension White-coat hypertension Poorly controlled hypertension Well controlled hypertension | 7 days or more blood pressure measurement | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
blood pressure monitoring, home, Asia
Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children

Study Overview
=================
Brief Summary
-----------------
This is a descriptive prospective community-based seroprevalence study. Primary objective: To determine the prevalence of specific antibodies (immunoglobulin G [IgG]) against dengue in healthy 5 to 10 year-old children in India. Secondary objectives: To determine the dengue virus serotype (DeNV-1,2,3 and /or 4) specific to the antibodies in positive (IgG) samples To estimate the prevalence of specific antibodies (IgG) against Japanese encephalitis in healthy 5 to 10 year-old children in India.

Official Title
-----------------
Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children in India

Conditions
-----------------
Dengue, Dengue Fever, Dengue Hemorrhagic Fever

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged between 5 and 10 year-old on the day of inclusion Healthy child as reported by the parent or legally qualified guardian Being registered in selected study site Provision of the informed consent form signed by at least one parent or legally qualified guardian For children between 8 and 10 years old, provision of the assent form signed. Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study Group<br>Participants aged between 5 and 10 year-old on day of inclusion. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of positive samples with dengue specific serotype DENV 1, 2,3 and/or 4 |  | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of positive serum samples with JEV specific IgG antibodies |  | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dengue, Dengue Fever, Dengue Hemorrhagic Fever
The Effect of Adding Dexamethasone to Epidural Bupivacaine for Total Knee Replacement Surgery

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to evaluate the efficacy of dexamethasone when added to epidural bupivacaine on the duration of postoperative analgesia in patients underwent total knee replacement surgery.

Detailed Description
-----------------
Fifty patients underwent total knee replacement were included in the study. The patients (11 male and 39 female) were classified into two equal groups:- The patients received 15 mL plain bupivacaine + 2 mL (BS), or 8 mg dexamethasone (BD). The total volume injected in both groups was 17 ml. Postoperative records: Pain score (NRS) at base line, then every 4 hrs for 24 hrs. Frequency of rescue analgesia. Postoperative side effects like nausea, vomiting, and over sedation.

Official Title
-----------------
The Effect of Adding Dexamethasone to Epidural Bupivacaine for Total Knee Replacement Surgery

Conditions
-----------------
Postoperative Pain

Intervention / Treatment
-----------------
* Drug: Dexamethasone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled for total knee replacement surgery. ASA Physical status I,II,III. Exclusion Criteria Patients' refusal. Uncooperative patients / Not able to understand pain assessment test. Patients with history of allergy to the used drugs. Significant liver disease. Pregnancy. Any contraindication for epidural anesthesia Failed technique.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: controlled group<br>Group І (control group): the patients received 15 ml epidural plain bupivacaine (0.5%) +2 ml normal saline Group (BS). | Drug: Dexamethasone<br>* dexamethasone + plain Bupivacaine injected epidurally.<br>* Other names: Decadrone;|
| Active Comparator: dexamethasone group<br>Group II (dexamethasone group):- the patients received 15 ml epidural plain bupivacaine (0.5%) + 8mg dexamethasone (2ml) Group (BD) | Drug: Dexamethasone<br>* dexamethasone + plain Bupivacaine injected epidurally.<br>* Other names: Decadrone;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| duration of postoperative analgesia (NRS) | first patient request for analgesia or NRS 4 or more | 24 hrs postoperative |
Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effects of adherence on HIV antiviral response to treatment regimens containing Kaletra or other HIV protease inhibitors.

Official Title
-----------------
Factors Associated With Adherence in a Cohort of HIV Positive Subjects on a First Time PI Containing HAART Regimen: Observational Study of the Impact of Adherence on Viral Load for a HAART Regimen Containing Kaletra vs Other Selected PI Containing HAART.

Conditions
-----------------
HIV Infection

Intervention / Treatment
-----------------
* Drug: Lopinavir/Ritonavir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is documented HIV positive Subject is greater than or equal to 18 years of age. Subject currently on a regimen of either NNRTI + 2 Nucleoside Reverse Transcriptase Inhibitors NRTIs), two or three NRTIs who have failed regimen as evidenced by two consecutive viral loads with values over 1,000 copies/mL, the last one within the last three months, or Naïve subjects to ARV regimen who are required to begin a PI containing HAART regimen, or Subjects who have become intolerant to their current antiretroviral regimen and are required to be changed to a first time PI containing HAART regimen. Subject had laboratory testing within the previous three months and the most recent testing demonstrates all of the following: Hemoglobin >8.0 g/dL; Absolute neutrophil count >750 cells/mL; Platelet count >20,000/mL; ALT or AST <3 x Upper Limit of Normal (ULN); Creatinine <1.5 x ULN; Triglycerides <750 mg/dL. Subjects have no have evidence of grade III or IV adverse event or laboratory abnormality. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lopinavir/Ritonavir|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Antiviral efficacy by HIV RNA |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment related discontinuations, predictors of adherence |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV Infection, HAART, Lopinavir, Ritonavir, Treatment Experienced, Treatment Naive